Article highlights
- Cutaneous adverse effects are the most prevalent immune-related
adverse events induced by anti-PD-1/PD-L1 immune-checkpoint
antibodies.
- Cutaneous toxicities mainly manifest in the form of maculopapular rash
and pruritus.
- More specific cutaneous complications can also occur, including
vitiligo, worsened psoriasis, lichenoid dermatitis, mucosal
involvement (e.g.oral lichenoid reaction), dermatomyositis, lupus
erythematosus.
- Cutaneous manifestations can be life-threatening including
stevens-johnson syndrome/toxic epidermal necrolysis (TEN).
- Dermatologic toxicities are usually mild, readily manageable, and
rarely result in significant morbidity.
- Adequate management of the cutaneous adverse event and recognition in
early stages could lead to the prevention of worsening of the lesions
and limit treatment disruption.